Macular Dystrophy: How This Rare Eye Disease Causes Blindness
Macular dystrophy is a relatively rare eye condition. Linked to inherited genetic mutations, macular dystrophy causes deterioration of the most sensitive part of the central retina (macula), which has the highest concentration of light-sensitive cells (
As the name implies, the macula of the retina is affected in macular dystrophy. The macula is the central area of the retina that contains photoreceptors responsible for central vision and color perception. When the macula is damaged or scarred due to macular dystrophy, your central vision is affected — and this can lead to blindness in some cases.
What Causes Macular Dystrophy?
While aging or risk factors such as smoking cause common forms of macular degeneration, macular dystrophy is linked to genetic mutations that — for no apparent reason — trigger degradation of retinal cells. Some forms of macular dystrophy appear in childhood, and other forms appear in adulthood.
However, it sometimes is difficult to distinguish common macular degeneration from inherited macular dystrophy because of the similarity of symptoms, including decreased visual acuity and loss of central vision.
One of the most common forms of macular dystrophy is Stargardt's disease, which accounts for about 7 percent of all macular dystrophy cases and commonly occurs in childhood.*
How Macular Dystrophy Is Diagnosed
Symptoms of macular dystrophy can include decreased visual acuity with no obvious cause, such ascataracts.
A test using
Still another option is an electroretinographic (ERG) test that involves placing an electrode on your eye's outer, clear surface (cornea) to measure how well photoreceptors in your retina respond to light.
Types of Macular Dystrophy
Many forms of macular dystrophy have been identified, including:
- Stargardt's, the most common type of macular dystrophy, which usually occurs in childhood. A different form of Stargardt's, called fundus flavimaculatus, typically is found in adults. Stargardt's is characterized by formation of pigmented waste cells in the retina.
- Vitelliform macular dystrophy (VTM), which generally is discovered first with the presence of a large, yellow oval lesion (vitelliform) in an egg yolk shape that shows up in the center of the macula. Many genetic mutations of this form of macular dystrophy have been identified, including Best's disease, which affects children and young people. A different version of the disease also can appear in adults, with macular lesions that vary in size and shape.
- North Carolina macular dystrophy, which is an extremely rare form of the eye disease identified by a very specific genetic marker. While named for North Carolina family members who have this inherited form of macular dystrophy, the disease has been found in other locations worldwide.
Other types of macular dystrophy can cause specific degeneration of light-sensitive cells known as
While not technically macular dystrophy, retinitis pigmentosa is an inherited photoreceptor dystrophy that destroys light-sensitive cells in the eye.
Treatments for Macular Dystrophy
If you have macular dystrophy, you will need to visit a retinal specialist who will help you determine the exact nature of the disease. For example, some types are progressive and some aren't.
Genetic analysis and counseling may be needed to help you determine the type of macular dystrophy you have and whether the eye condition is likely to be passed on to your children and descendants. Also, you can make better decisions about family planning if you have an idea of the degree of vision loss associated with your type of macular dystrophy.
At this time, there is no proven treatment for macular dystrophy. However, gene therapy has shown promise for treating this and other types of genetic diseases.
For example, Ocata Therapeutics has presented results of several prospective trials that evaluated the use of retinal pigment epithelial (RPE) cells derived from human embryonic stem cells for the treatment of Stargardt's disease. So far, 31 patients have been treated, all of whom experienced improved or table, best-corrected visual acuity (BCVA).
Page updated December 2017